Natalizumab in Multiple Sclerosis: Long-Term Management

Natalizumab is a monoclonal antibody highly effective in the treatment of relapsing remitting multiple sclerosis (RRMS) patients. Despite its effectiveness, there are growing concerns regarding the risk of progressive multifocal leukoencephalopathy (PML), a brain infection caused by John Cunningham...

Descripción completa

Detalles Bibliográficos
Autores principales: Clerico, Marinella, Artusi, Carlo Alberto, Di Liberto, Alessandra, Rolla, Simona, Bardina, Valentina, Barbero, Pierangelo, De Mercanti, Stefania Federica, Durelli, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454853/
https://www.ncbi.nlm.nih.gov/pubmed/28468254
http://dx.doi.org/10.3390/ijms18050940

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5454853/
https://www.ncbi.nlm.nih.gov/pubmed/28468254
http://dx.doi.org/10.3390/ijms18050940

Ejemplares similares